Chemotherapy and its evolving role in the management of advanced prostate cancer Por Michael T Schweizer, Emmanuel S Antonarakis

Obter o texto integral

Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born Por Michael T. Schweizer, Emmanuel S. Antonarakis

Obter o texto integral

Targeting intratumoral androgens: statins and beyond Por Michael T. Schweizer, Evan Y. Yu

Obter o texto integral

Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate ca... Por Michael Lai, Evan Y Yu, Michael T Schweizer, Darien E Reed-Perino

Obter o texto integral

Hormone levels following surgical and medical castration: defining optimal androgen suppression Por Michael T Schweizer, Michael L Hancock, Robert H Getzenberg, Evan Y Yu

Obter o texto integral

Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss Por Mark C. Markowski, Hao Wang, Angelo M. De Marzo, Michael T. Schweizer, Emmanuel S. Antonarakis, Samuel R. Denmeade

Obter o texto integral

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. Por Laura S Graham, Bruce Montgomery, Heather H Cheng, Evan Y Yu, Peter S Nelson, Colin Pritchard, Stephanie Erickson, Ajjai Alva, Michael T Schweizer

Obter o texto integral

Microsatellite instability in prostate cancer by PCR or next-generation sequencing Por Jennifer A. Hempelmann, Christina M. Lockwood, Eric Q. Konnick, Michael T. Schweizer, Emmanuel S. Antonarakis, Tamara L. Lotan, Bruce Montgomery, Peter S. Nelson, Nola Klemfuss, Stephen J. Salipante, Colin C. Pritchard

Obter o texto integral

Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer Por Alexander S. Carlson, Rigo I. Acevedo, Daniel M. Lim, Roman Gulati, Agnes Gawne, Alexandra O. Sokolova, Heather H. Cheng, Peter S. Nelson, R. Bruce Montgomery, Evan Y. Yu, Michael T. Schweizer, Alvaro Galli

Obter o texto integral

Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. Por Michael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, Roman Gulati, Heather H Cheng, Jessica L Maes, Ruth F Dumpit, Peter S Nelson, Bruce Montgomery, Jeannine S McCune, Stephen R Plymate, Evan Y Yu

Obter o texto integral

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. Por Michael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, Roman Gulati, Heather H Cheng, Jessica L Maes, Ruth F Dumpit, Peter S Nelson, Bruce Montgomery, Jeannine S McCune, Stephen R Plymate, Evan Y Yu

Obter o texto integral

In Reply Por W. Nathaniel Brennen, Michael T. Schweizer, Hao Wang, Trinity J. Bivalacqua, Alan W. Partin, Su Jin Lim, Carolyn Chapman, Rehab Abdallah, Oren Levy, Neil A. Bhowmick, Jeffrey M. Karp, Angelo De Marzo, John T. Isaacs, Samuel R. Denmeade

Obter o texto integral

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer Por Navonil De Sarkar, Sayan Dasgupta, Payel Chatterjee, Ilsa Coleman, Gavin Ha, Lisa S. Ang, Emily A. Kohlbrenner, Sander B. Frank, Talina A. Nunez, Stephen J. Salipante, Eva Corey, Colm Morrissey, Eliezer Van Allen, Michael T. Schweizer, Michael C. Haffner, Radhika Patel, Brian Hanratty, Jared M. Lucas, Ruth F. Dumpit, Colin C. Pritchard, Robert B. Montgomery, Peter S. Nelson

Obter o texto integral

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-res... Por Tian Zhang, Nicholas J Vogelzang, Daniel P Petrylak, Ravi A Madan, Karen A Autio, Ray Li, Helen Cho, Szu-Yu Tang, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Xin-Hua Zhu, Hani Babiker, Sandip M Prasad, Michael T Schweizer, Stephane Billotte, Nora Cavazos, Orlaith Bogg, Kam Chan, Megan Kaneda, I-Ming Wang, Jenny Zheng, Robert Hollingsworth, Kenneth A Kern

Obter o texto integral

Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer Por Erolcan Sayar, Radhika A. Patel, Ilsa M. Coleman, Martine P. Roudier, Ailin Zhang, Pallabi Mustafi, Jin-Yih Low, Brian Hanratty, Lisa S. Ang, Vipul Bhatia, Mohamed Adil, Hasim Bakbak, David A. Quigley, Michael T. Schweizer, Jessica E. Hawley, Lori Kollath, Lawrence D. True, Felix Y. Feng, Neil H. Bander, Eva Corey, John K. Lee, Colm Morrissey, Roman Gulati, Peter S. Nelson, Michael C. Haffner

Obter o texto integral

Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates Por Azra Ajkunic, Erolcan Sayar, Martine P. Roudier, Radhika A. Patel, Ilsa M. Coleman, Navonil De Sarkar, Brian Hanratty, Mohamed Adil, Jimmy Zhao, Samir Zaidi, Lawrence D. True, Jamie M. Sperger, Heather H. Cheng, Evan Y. Yu, Robert B. Montgomery, Jessica E. Hawley, Gavin Ha, Thomas Persse, Patricia Galipeau, John K. Lee, Stephanie A. Harmon, Eva Corey, Joshua M. Lang, Charles L. Sawyers, Colm Morrissey, Michael T. Schweizer, Roman Gulati, Peter S. Nelson, Michael C. Haffner

Obter o texto integral